Celldex Therapeutics, Inc. CLDX
- barzolvolimab — Chronic Spontaneous Urticaria Phase 3
- barzolvolimab — Symptomatic Dermographism Phase 3
- barzolvolimab — Atopic Dermatitis Phase 2
- barzolvolimab — Chronic Inducible Urticaria Phase 3
KIT (3 companies · 6 programs)
Companies with an active program directed at KIT.
Cogent Biosciences, Inc. COGT
- bezuclastinib — Gastrointestinal Stromal Tumor NDA Submitted
ENANTA PHARMACEUTICALS INC ENTA
- EDP-978 — Chronic Spontaneous Urticaria Phase 1